How to buy Eagle Pharmaceuticals stock (EGRX)

Eagle Pharmaceuticals is a drug manufacturers - specialty & generic business based in the US. Eagle Pharmaceuticals shares (EGRX) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $0.40 – a decrease of 37.5% over the previous week. Eagle Pharmaceuticals employs 134 staff and has a trailing 12-month revenue of around $257.6 million.

Our top picks for where to buy Eagle Pharmaceuticals stock

Buy Eagle Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Eagle Pharmaceuticals stock price (PINK: EGRX)

Use our graph to track the performance of EGRX stocks over time.

Eagle Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-10-25.

Latest market close	$0.40
52-week range	$0.10 - $14.78
50-day moving average more info button	$3.13
200-day moving average more info button	$4.51
Wall St. target price	$17.00
PE ratio more info button	0.8235
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$0.85

Eagle Pharmaceuticals price performance over time

Historical closes compared with the close of $0.6 from 2024-10-25

1 week (2024-10-22)	-14.29%
1 month (2024-09-30)	-83.91%
3 months (2024-07-30)	-87.34%
6 months (2024-04-30)	-85.33%

1 year (2023-10-30)	-95.68%
2 years (2022-10-28)	-98.18%
3 years (2021-10-29)	52.37
5 years (2019-10-30)	63.41

Is Eagle Pharmaceuticals stock undervalued or overvalued?

Valuing Eagle Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Eagle Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Eagle Pharmaceuticals's P/E ratio

Eagle Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Eagle Pharmaceuticals shares trade at around 1x recent earnings.

Eagle Pharmaceuticals's PEG ratio

Eagle Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.91. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Eagle Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Eagle Pharmaceuticals's EBITDA

Eagle Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $62.3 million.

The EBITDA is a measure of a Eagle Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Eagle Pharmaceuticals financials

Revenue TTM	$257.6 million
Operating margin TTM	15.94%
Gross profit TTM	$221.7 million
Return on assets TTM	6.63%
Return on equity TTM	4.88%
Profit margin	4.64%
Book value	$19.25
Market Capitalization more info button	$9.1 million

TTM: trailing 12 months

Eagle Pharmaceuticals share dividends

We're not expecting Eagle Pharmaceuticals to pay a dividend over the next 12 months.

Eagle Pharmaceuticals share price volatility

Over the last 12 months, Eagle Pharmaceuticals's shares have ranged in value from as little as $0.1 up to $14.78. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Eagle Pharmaceuticals's is 0.519. This would suggest that Eagle Pharmaceuticals's shares are less volatile than average (for this exchange).

Eagle Pharmaceuticals overview

Eagle Pharmaceuticals, Inc. , a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas.

Frequently asked questions

null
What percentage of Eagle Pharmaceuticals is owned by insiders or institutions?
Currently 12.023% of Eagle Pharmaceuticals shares are held by insiders and 78.797% by institutions. How many people work for Eagle Pharmaceuticals?
Latest data suggests 134 work at Eagle Pharmaceuticals. When does the fiscal year end for Eagle Pharmaceuticals?
Eagle Pharmaceuticals's fiscal year ends in December. Where is Eagle Pharmaceuticals based?
Eagle Pharmaceuticals's address is: 50 Tice Boulevard, Woodcliff Lake, NJ, United States, 07677 What is Eagle Pharmaceuticals's ISIN number?
Eagle Pharmaceuticals's international securities identification number is: US2697961082 What is Eagle Pharmaceuticals's CUSIP number?
Eagle Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 269796108